Analysis of the reasons why some patients are not recommended to take Tepotinib (Tuodekang)

Tepotinib is an oral METtyrosine kinase inhibitor, mainly used to treat METexon14 non-small cell lung cancer patients with positive skipping mutations. Although the drug has shown good clinical efficacy, not all patients are suitable for use. Due to underlying diseases, physical conditions or potential risk factors, taking tepotinib may cause adverse reactions or affect the safety of treatment in some patients, so careful evaluation is required.

First, the use of tepotinib is not recommended in patients with hepatic impairment. The drug is mainly metabolized by the liver. If the patient has obvious liver damage or abnormal liver function, the metabolism and elimination ability of the drug in the body may decrease, resulting in an increase in blood drug concentration, thereby increasing the risk of adverse reactions, such as severe edema, liver damage, or abnormal blood indicators. Therefore, doctors will evaluate liver function indicators before prescribing and adjust the dose or choose other treatment options if necessary.

Secondly, patients with heart disease also need to be cautious. Tepotinib may cause edema or increase in blood pressure. For patients with severe heart failure, hypertension or arrhythmias, the use of this drug may increase the burden on the heart and increase the risk of cardiovascular events. For such patients, doctors usually recommend controlling underlying heart disease first, or choosing other treatment drugs with lower risks to ensure drug safety.

In addition, the use of tepotinib is not recommended for pregnant and lactating women. Because the drug has been shown to be potentially toxic to the fetus in animal experiments and there is no sufficient clinical data to confirm its safety, there are potential risks when used during pregnancy or lactation. At the same time, some patients with severe renal insufficiency or who are highly sensitive to drug ingredients should also be used with caution under doctor's evaluation, and alternative options should be selected when necessary to reduce the incidence of adverse reactions and ensure safe and effective treatment.

Reference link:https://www.drugs.com